ReviewCurrent opinion in microbiology2020
Pseudomonas aeruginosa polymicrobial interactions during lung infection.
Review in Current opinion in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- A Chirality-Converted Bacteriolytic Dodecapeptide Regulates Vibrio-Induced Polymicrobial Infection and Ameliorates Invasion-Associated Gut Microbiota Disequilibrium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Copper-driven mutualism ofMicrobiology (Reading, England) · 2026Article
- Review
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Bacterial quorum-sensing systems in cell-cell communication.FEMS microbiology reviews · 2026Review
- Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates.Microbiological research · 2025Article
- Itaconate utilisation by the human pathogen Pseudomonas aeruginosa requires uptake via the IctPQM TRAP transporter.The Biochemical journal · 2025Article
- Different aspects of Pseudomonas aeruginosa biofilm: an in-depth analysis from formation to detection.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Isolation, Identification, and Drug Sensitivity Test ofVeterinary sciences · 2025Article
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
- Cross-talk between Pseudomonas aeruginosa and urinary tract infections.World journal of urology · 2025Review
- MvfR ShapesCells · 2025Article
- Inhibiting NLRP3 enhances cellular autophagy induced by outer membrane vesicles fromMicrobiology spectrum · 2025Article
- Article
- Exploring Tenebrio molitor as a source of low-molecular-weight antimicrobial peptides using a n in silico approach: correlation of molecular features and molecular docking.Journal of the science of food and agriculture · 2025Article
- Green Nanotechnology: Naturally Sourced Nanoparticles as Antibiofilm and Antivirulence Agents Against Infectious Diseases.International journal of microbiology · 2025Review
- The effects of silver nitrate onFrontiers in public health · 2025Article
- Furazolidone reduces the pathogenesis ofHeliyon · 2024Article
- Interspecies surfactants serve as public goods enabling surface motility inJournal of bacteriology · 2024Article
- Interactions between Pseudomonas aeruginosa and six opportunistic pathogens cover a broad spectrum from mutualism to antagonism.Environmental microbiology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic infections often contain complex polymicrobial communities that are recalcitrant to antibiotic treatment. The pathogens associated with these infectious communities are often studied in pure culture for their ability to cause disease. However, recent studies have begun to focus on the role of polymicrobial interactions in disease outcomes. Pseudomonas aeruginosa can colonize patients with chronic lung diseases for years and sometimes even decades. During these prolonged infections, P. aeruginosa encounters a plethora of other microbes including bacteria, fungi, and viruses. The interactions between these microbes can vary greatly, ranging from antagonistic to synergistic depending on specific host and microbe-associated contexts. These additional layers of complexity associated with chronic P. aeruginosa infections must be considered in future studies in order to fully understand the physiology of infection. Such studies focusing on the entire infectious community rather than individual species may ultimately lead to more effective therapeutic design for persistent polymicrobial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.